{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:46:01Z","timestamp":1782906361276,"version":"3.54.5"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Determining an optimal treatment strategy after tyrosine kinase inhibitor (TKI) failure remains challenging in oncogene-driven non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      We aimed to evaluate and compare the efficacy and safety of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) versus pemetrexed plus carboplatin or cisplatin (PC) in patients with progressive NSCLC harboring\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      , or\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      alterations after TKI failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Multicenter retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We analyzed 114 patients with NSCLC treated with either ABCP (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200948) or PC (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200966) post-TKI failure between November 2016 and July 2023. Treatment response, progression-free survival (PFS), overall survival (OS), and safety profiles were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 106 evaluable participants, the ABCP arm demonstrated a higher response rate (50.0%) than the PC arm (35.0%). During the median follow-up of 29.9\u2009months, PFS was significantly prolonged in the ABCP arm compared with that in the PC arm (7.3 vs 3.0\u2009months, respectively; hazard ratio (HR) 0.643;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.026), whereas OS showed no significant difference (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.165). Subgroup analysis revealed notable improvements in PFS (7.2 vs 2.1\u2009months, HR 0.235;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and OS (11.0 vs 4.1\u2009months, HR 0.418;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001) in patients with three or more metastatic sites.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ABCP significantly improved PFS compared with PC in patients with NSCLC that progressed despite prior TKI therapy. An OS benefit was observed in patients with three or more metastatic sites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261458751","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:36Z","timestamp":1782518436000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-4912","authenticated-orcid":false,"given":"Moonki","family":"Hong","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Division of Hemato-Oncology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junho","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-2479","authenticated-orcid":false,"given":"Seoyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Beom","family":"Sang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hee","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Hyun","family":"Yeo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Gon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-9070","authenticated-orcid":false,"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00762"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00515"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1415359"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0020"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy554"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.003"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_3_4_18_2","first-page":"41","article-title":"CheckMate-722: the rise and fall of nivolumab with chemotherapy in TKI-refractory EGFR-mutant NSCLC","volume":"14","author":"Lee ATM","year":"2023","unstructured":"Lee ATM, Nagasaka M. CheckMate-722: the rise and fall of nivolumab with chemotherapy in TKI-refractory EGFR-mutant NSCLC. Lung Cancer (Auckl) 2023; 14: 41\u201346.","journal-title":"Lung Cancer (Auckl)"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01891"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00135-2"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113469"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14836"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16210"},{"key":"e_1_3_4_27_2","article-title":"Combination therapy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor resistance and EGFR mutations","volume":"16","author":"Kobayashi H","year":"2024","unstructured":"Kobayashi H, Otsuki A, Ikeda S, et al. Combination therapy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor resistance and EGFR mutations. Cureus 2024; 16: e67307.","journal-title":"Cureus"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00912"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.185"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30084-0"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000645"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.10.002"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.014"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613"},{"key":"e_1_3_4_37_2","article-title":"1348 final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR\u2009+\u2009NSCLC progressed on EGFR-TKI treatment","volume":"13","author":"Zhang L","year":"2025","unstructured":"Zhang L, Fang W, Zhao Y, et al. 1348 final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR\u2009+\u2009NSCLC progressed on EGFR-TKI treatment. J ImmunoTher Cancer 2025; 13: A1592\u2013A1592.","journal-title":"J ImmunoTher Cancer"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100778"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261458751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261458751","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261458751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:55:01Z","timestamp":1782903301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261458751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["10.1177\/17588359261458751"],"URL":"https:\/\/doi.org\/10.1177\/17588359261458751","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17588359261458751"}}